Y-mabs announces submission of omburtamab biologics license application to fda

New york, april 01, 2022 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on march 31, 2022, the company completed the resubmission of its biologics license application (“bla”) for 131i-omburtamab (“omburtamab”) to the fda.
YMAB Ratings Summary
YMAB Quant Ranking